Abstract:Arterial and venous thromboembolism is a major medical concern that requires therapeutic anticoagulation in various medical fields to prevent its drastic consequences. Despite significant advances in anticoagulant therapy, thrombosis remains a leading cause of morbidity and mortality worldwide. Traditional anticoagulants like heparin and vitamin K antagonists (VKAs) have shown efficacy in preventing and treating thrombosis but come with an inherent risk of bleeding due to their non-specific inhibition of multiple coagulation factors. Subsequent direct oral anticoagulants (DOACs), targeting specific factors such as Xa or thrombin, demonstrated improved safety profiles compared to VKAs, yet bleeding remains a concern. Accordingly, research is focused on developing anticoagulants with improved safety profiles. A safer class of anticoagulants would have broad appeal. The intrinsic pathway of coagulation, involving factor XI (FXI), has attracted attention as a potential target for safer anticoagulants. Preclinical studies and epidemiological data indicate that FXI deficiency or inhibition protects against thrombosis with minimal bleeding. Current research involves evaluating various FXI-directed strategies, and phase 2 studies have shown promising results in orthopedic surgery, atrial fibrillation, end-stage renal disease (ESRD), myocardial infarction, and ischemic stroke. Several agents, such as antisense oligonucleotides, monoclonal antibodies, small synthetic molecules, natural peptides, and aptamers, have been developed to inhibit FXI at different stages, offering potentially safer alternatives to traditional anticoagulants. However, the optimal balance between preventing thrombosis and the risk of bleeding associated with FXI inhibitors requires validation through extensive phase 3 clinical trials using definite clinical endpoints. Several of such trials are currently underway or planned to define the role of FXI inhibitors in clinical practice and determine the most suitable FXI inhibitor for each specific indication. The current review highlights the rationale behind developing FXI inhibitors, presenting the most advanced agents in development, summarizing completed clinical trials, and discussing ongoing research efforts.

Roles of platelets and factor XI in the initiation of blood coagulation by thrombin

Thrombin activation of the factor XI dimer is a multistaged process for each subunit

The effect of factor XIa on thrombin and plasmin generation, clot formation, lysis and density in coagulation factors deficiencies

Impact of Deficiency of Intrinsic Coagulation Factors XI and XII on Ex Vivo Thrombus Formation and Clot Lysis

Tissue factor pathway inhibitor – cofactor-dependent regulation of the initiation of coagulation

Factor XI and coagulation. Factor XI inhibitors - antithrombotic perspectives

Introduction to a review series on factor XI

Role of Factor XIa and Plasma Kallikrein in Arterial and Venous Thrombosis

Clinical, Laboratory Aspects and Management of Factor X Deficiency

Phosphorylation of coagulation factor XI by a casein kinase released by activated human platelets increases its susceptibility to activation by factor XIIa and thrombin

Factor XI Homodimer Structure is Essential for Normal Proteolytic Activation by Factor XIIa, Thrombin, and Factor XIa.

Inherited factor X deficiency: molecular genetics and pathophysiology

Binding of coagulation factor IXa to procoagulant platelets revisited: Low affinity and interactions with other factors

Inhibition of platelet-surface-bound proteins during coagulation under flow I: TFPI

Structure–Function Relationship of the Interaction between Tissue Factor and Factor VIIa

Factor XI: structure, function and therapeutic inhibition

Laboratory and Molecular Diagnosis of Factor XI Deficiency

Coagulation Factor XIIIa and Activated Protein C Activate Platelets via GPVI and PAR1

In vivo activation and functions of the protease factor XII

A Novel Mouse Whole Blood Thrombin Generation Assay Sensitive to FXI- and FIX-mediated Amplification of Coagulation

Hageman Factor, Platelets And Polyphosphates: Early History And Recent Connection